SCHEMBL18486291

SCHEMBL18486291

c1ccc2sc(-c3ncnc4nc[nH]c34)cc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKT2 P31751 6/20 0.44
▸ JAK2 O60674 1/20 0.43
▸ JAK3 P52333 1/20 0.43
▸ PIK3CD O00329 1/20 0.43
▸ PIK3CA P42336 1/20 0.43
▸ PIK3CB P42338 1/20 0.43
▸ PIK3CG P48736 1/20 0.43
▸ PRKDC P78527 1/20 0.43
▸ EGFR P00533 4/20 0.42
▸ CDC7 O00311 2/20 0.42
▸ DBF4 Q9UBU7 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ IGF1R P08069 1/20 0.42
▸ SRC P12931 1/20 0.42
▸ EPHB4 P54760 1/20 0.42
▸ PRKACA P17612 3/20 0.41
▸ PRKACG P22612 3/20 0.41
▸ PRKACB P22694 3/20 0.41
▸ MAPK14 Q16539 1/20 0.41
▸ STK17B O94768 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7027580 0.73 MAPK14 (0.47) AKT2CDC7KDRSRCPRKACA
SCHEMBL23077807 0.72 PIK3CD (0.45) JAK2JAK3PIK3CDPIK3CAPIK3CB
SCHEMBL1029868 0.72 SMN1; SMN2 (0.51) AKT2PIK3CAPIK3CGKDRPRKACA
SCHEMBL2938675 0.71 AKT2 (0.70) AKT2EGFRCDC7DBF4PRKACA
SCHEMBL18486241 0.69 PIK3CA (0.46) AKT2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3778190 0.68 AKT2 (0.48) AKT2EGFRCDC7DBF4PRKACA
SCHEMBL22342532 0.68 ADORA2A (0.61) JAK2JAK3PIK3CDPIK3CAPIK3CB
SCHEMBL3492637 0.67 AKT2 (0.50) AKT2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL845603 0.67 APP (0.63) —
SCHEMBL29732980 0.67 APP (0.63) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3130597-B1 OLIGONUCLEOTIDE HAVING A NON-NATURAL NUCLEOTIDE AT THE 5'-TERMINAL KYOWA KIRIN CO LTD (JP) 2021-11-10 — — EP disclosed
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof KYOWA HAKKO KIRIN CO., LTD. (JP) 2019-07-09 — — US disclosed
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-12-14 — — US disclosed
EP-3130597-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF Kyowa Hakko Kirin Co., Ltd. (JP) 2017-02-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10342819-B2 Oligonucleotide having non-natural nucleotide at 5′-terminal thereof RNGTT, UPF1, NSUN3 AKT2 3555/4885JAK2 2964/4885JAK3 2798/4885
US-20170354673-A1 OLIGONUCLEOTIDE HAVING NON-NATURAL NUCLEOTIDE AT 5'-TERMINAL THEREOF RNGTT, UPF1, NSUN3 AKT2 3611/4885JAK2 3034/4885JAK3 2833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback